Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days

Clinical Cancer Research

Volumn 8, Issue 8, 2002, Pages 2524-2529

  Stevenson, James P ^a   Sun, Weijing ^a   Gallagher, Maryann ^a   Johnson, Robert ^b   Vaughn, David ^a   Schuchter, Lynn ^a   Algazy, Kenneth ^a   Hahn, Stephen ^a   Enas, Nathan ^b   Ellis, Diane ^b   Thornton, Donald ^b   O'Dwyer, Peter J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CRYPTOPHYCIN; CRYPTOPHYCIN 52; CYCLOPEPTIDE; DEPSIPEPTIDE; LACTAM; LACTONE; CRYPTOPHYCIN DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER TRANSPLANTATION; CHEMICAL MODEL; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MIDDLE AGED; NEOPLASM; PHASE 1 CLINICAL TRIAL; PHENOTYPE; THEORETICAL MODEL; TIME; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DISTRIBUTION VOLUME; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG RESPONSE; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN TISSUE; ILEUS; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MOTOR NEUROPATHY; MYALGIA; NAUSEA; NEUROTOXICITY; PLASMA CLEARANCE; PRIORITY JOURNAL; STRUCTURE ANALYSIS; TANDEM MASS SPECTROMETRY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LACTAMS; LACTONES; MALE; MIDDLE AGED; MODELS, CHEMICAL; MODELS, THEORETICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; PEPTIDES, CYCLIC; PHENOTYPE; TIME FACTORS; HUMAN; MIDDLE AGE;

EID: 0036023410     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pharmaceuticals from cultured algae
2. Total structures of cryptophycins, potent antitumor depsipeptides from the blue-green alga Nostoc sp. Strain GSV
3. Mechanism of action of cryptophycin. Interaction with the Vinca alkaloid domain of tubulin
4. Antiproliferative mechanism of action of cryptophycin-52: Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends
5. In vitro antiproliferative activity of the epoxide cryptophycin analogue, LY355703
6. Preclinical antitumor activity of cryptophycin-52/55 (C-52;C-55) against mouse tumors
7. Preclinical antitumor activity of cryptophycin-52/55 (C-52;C-55) against human tumors in SCID mice
8. LY355702 and LY355703, new cryptophycin analogues with antitumor activity against human tumor xenografts
9. Cryptophycin: A new antimicrotubule agent active against drug-resistant cells
10. In vitro pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines
11. Reporting results of cancer treatment
12. Practical modifications of the continual reassessment method for Phase I cancer clinical trials
13. Determination of LY355703 in dog and mouse plasma by positive ion liquid chromatography/tandem mass spectrometry with atmospheric pressure chemical ionization
14. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects
15. Phase I clinical and pharmacokinetic study of Taxol
16. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics
17. Neurotoxicity of vincristine
18. Pharmacology of antitumor agents from higher plants
19. Neurotoxicity of Taxol
20. Pain at tumor site after vinorelbine injection: Description of an unexpected side effect